Latest News, Grants & Research Reports

Read our latest news, blog posts and research updates right here

Come and join us!
Alex Bremer Alex Bremer

Come and join us!

Neuroblastoma UK is looking for new Trustees and volunteers to join us in our mission to fund new, effective and kinder treatments for children with neuroblastoma. Help us shape how the charity makes the greatest difference for these children in the future.

Read More
Annual Conference in Bristol
Guest User Guest User

Annual Conference in Bristol

Our Annual Conference was held at Bristol University in September.  We were delighted to hear from Dr Karim Malik and his team about the work we are funding in collaboration with Smile with Siddy.

Read More
ANR 2016 Parents' Day
Guest User Guest User

ANR 2016 Parents' Day

Videos of talks made at the Parents Day during the Advances in Neuroblastoma Research Congress 2016 held in Cairns, Australia, in June this year and at the Neuroblastoma Update day are now available to download.

Read More
The Cost of Cancer
Guest User Guest User

The Cost of Cancer

CLIC Sargent's Cancer Costs report and campaign looks specifically at the financial cost of cancer and how these costs impact families. Cancer costs is part of CLIC Sargent’s three year Better care for young cancer patients campaign which launched in July 2015 to secure better care for young cancer patients in the UK.

Read More
Thank you to our 2016 Prudential RideLondon 100 team
Alex Bremer Alex Bremer

Thank you to our 2016 Prudential RideLondon 100 team

Thank you to our Prudential RideLondon 100 team who took on the challenge of cycling this great event from the Queen Elizabeth Olympic Park through the streets of London and into the countryside of Surrey returning to finish on the Mall.

Read More
Cancer Drugs Fund
Alex Bremer Alex Bremer

Cancer Drugs Fund

Cancer52, an alliance of 90 organisations representing less common cancers, has published a briefing paper on the new Cancer Drugs Fund operating model. It provides an overview of the key features of the new model and the current Cancer52 position on the impact it may have on access to cancer drugs in England.

Read More